Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416410 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| Hydrochloric Acid SCHEMBL5739823 | 0.98 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL856909 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL29793572 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL145141 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL856547 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL20813787 | 0.79 | NR4A2 (0.47) | NR4A2SOS2CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL22911854 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL858150 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL6442231 | 0.79 | NR4A2 (0.56) | NR4A2SOS2CYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105892-B | FAK/PLK1 double-target quinazoline derivative and preparation method and application thereof | 浙江科技学院 | 2024-03-26 | — | — | CN | claimed |
| CN-114105892-A | FAK/PLK1 dual-target quinazoline derivative and preparation method and application thereof | 浙江科技学院 | 2022-03-01 | — | — | CN | claimed |
| JP-59013765-A | — | — | None | — | — | JP | disclosed |
| EP-3968404-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260059936-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4651875-A2 | QUINAZOLINE COMPOUNDS AND USES | Prosetta Biosciences, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4010330-B1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | HIRUNDO BIOSCIENCES (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-4808715-A | HYPERTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| US-4734510-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1988-03-29 | — | — | US | disclosed |
| US-4675047-A | MONOCOTYLEDON WEES | ICI AUSTRALIA LIMITED, 1 NICHOLSON ST., MELBOURNE, VICTORIA, 3000, AUSTRALIA, A CORP. OF AUSTRALIA | 1987-06-23 | — | — | US | disclosed |
| US-4640920-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1987-02-03 | — | — | US | disclosed |
| US-4464375-A | ANALGESIC, ANTIINFLAMMATORY | SANKYO CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| JP-S5913765-A | 2-(4-QUINAZOLINYL)AMINOBENZOIC ACID DERIVATIVE | KYORIN PHARMACEUT CO LTD | 1984-01-24 | — | — | JP | disclosed |
| US-4322420-A | Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
| EP-0044163-A2 | Quinazolinyloxy(amino)phenoxyalkane carboxylic acid derivatives, process for their synthesis, herbicidal compositions containing them and their use as herbicides | ICI AUSTRALIA LIMITED (AU) | 1982-01-20 | — | — | EP | disclosed |
| US-3931179-A | ANTIOBESITY | SANDOZ INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PDE4A 3891/4885PDE4B 3849/4885PDE4C 4382/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885 |
| US-20260059936-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, GLRB, GLRA1 | PDE4A 4879/4885PDE4B 4878/4885PDE4C 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.